Journal of Nanomedicine & Nanotechnology

Impact of nanobiotechnology on the future of medicine (nanomedicine): The road toward precision medicine

15^th World Medical Nanotechnology Congress

October 18-19, 2017 Osaka, Japan

Shaker A Mousa

Albany College of Pharmacy and Health Sciences, USA

Keynote: J Nanomed Nanotechnol

Abstract:

Over the past few years, evidence from the scientific and medical communities has demonstrated that nanotechnology and nanomedicine have tremendous potential to profoundly impact numerous aspects of cancer and other disorders in term of early diagnosis and targeted therapy. The utilization of nanotechnology for the development of new nanocarrier systems has the potential to offer improved chemotherapeutic delivery through increased solubility and sustained retention. One of the major advantages of this cutting-edge technology is its unique multifunctional characteristics. Targeted delivery of drug incorporated nanoparticles, through conjugation of tumor-specific cell surface markers, such as tumor-specific antibodies or ligands, which can enhance the efficacy of the anticancer drug and reduce the side effects. Additionally, multifunctional characteristics of the nanocarrier system would allow for simultaneous imaging of tumor mass, targeted drug delivery and monitoring (Theranostics). A summary of recent progress in nanotechnology as it relates specifically to nanoparticles and anti-cancer drug delivery will be reviewed. Nano nutraceuticals using combination of various natural products provide a great potential in diseases prevention. Additionally, various nanomedicine approaches for the detection and treatment of various types of organ specific delivery, vascular targeting and vaccine will be briefly discussed.

Biography :

Shaker A Mousa has completed his PhD from Ohio State University, College of Medicine in Columbus and Postdoctoral Fellowship from University of Kentucky in Lexington. He also has completed his MBA from Widener University, Chester, PA. He is currently an endowed tenure Professor and Executive Vice-President and Chairman of the Pharmaceutical Research Institute and Vice Provost for Research at ACPHS. He holds over 350 US and international patents discovering novel anti-angiogenesis strategies, anti-thrombotics, anti-integrins, anti-cancer and non-invasive diagnostic imaging approaches employing various nanotechnology platforms. He has published more than 1,000 journal articles, book chapters, published patents and books as editor and author. He is a Member of several NIH study sections and the Editorial Board of several high impact journals. His research has focused on diagnostics and therapeutics of angiogenesis-related disorders, thrombosis, vascular and cardiovascular diseases.